Dulaglutide Passes BP HurdleDulaglutide Passes BP Hurdle
Both doses of dulaglutide tested in the phase 2 study met the end point of noninferiority for 24-hour mean systolic blood pressure, but only the 1.5-mg dose was superior to placebo for reducing blood pressure. Heart rate was increased with the 1.5-mg dose, although the clinical significance of the increase remains to be determined. Heartwire (Source: Medscape Today Headlines)
175 A disappearing act: a tale of immunosuppression, EBV and CNS B-cell lymphoma
This 41-year-old woman with proven Ulcerative Colitis had been managed with Asacol, Prednisolone and Azathioprine. Eighteen months after commencement of Azathioprine (2nbsp;mg/kg/day) she developed a sub-acute severe encephalopathy. Azathioprine was discontinued on transfer to the Neurology unit. MRI imaging demonstrated numerous subcortical cerebral and cerebellar lesions. The differential diagnosis included an atypical infective process or metastases. CSF was normal with no cytological evidence of malignancy. JC virus, HIV negative. CT of chest abdomen and pelvis showed pulmonary nodules and bilateral adrenal masses. Adrenal biopsies/bronchoscopy normal. Serial MRI over 10nbsp;weeks demonstrated marked improvement except for an enlarging cerebellar lesion. Her condition greatly improve...
